Prime picks both in HCV

Prime Therapeutics LLC (Eagan, Minn.) is the latest pharmacy benefit manager to wade into the HCV price war. On Monday, the PBM said it would cover both Harvoni ledipasvir/ sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) and Viekira Pak from AbbVie Inc. (NYSE:ABBV).

Prime SVP of Integrated Care and Specialty Peter Wickersham told BioCentury the PBM picked both regimens over having a single exclusive option because "the co-preferred position has the best advantages in both cost and access for our clients and members. It also became very clear that neither Gilead nor AbbVie wanted to be left off formulary. We secured market-leading rates from both companies on both sets of products, providing significantly better value than exclusive deals." ...